At a glance
- Originator Fujisawa
- Class Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 02 Jul 2001 No-Development-Reported for Cognition disorders in Japan (PO)
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 08 Feb 1995 Preclinical development for Cognition disorders in Japan (PO)